NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
Rhea-AI Summary
NeOnc Technologies (Nasdaq:NTHI) received Investigational New Drug (IND) clearance from the Department of Health – Abu Dhabi for NEO212, its oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors.
The decision follows completion of Phase 1 dose escalation, which selected 610 mg as the recommended Phase 2 dose and showed encouraging early signs of activity in recurrent glioblastoma and brain metastases. The UAE authorization enables planned Phase 2 development, complements ongoing U.S. FDA discussions on a potential registrational pathway, and marks NEO212’s first international regulatory clearance. NeOnc must still obtain Institutional Review Board approval and update study documents before UAE enrollment, and the clearance does not allow marketing. NeOnc has also applied to DOH Abu Dhabi for its NEO100 programs (NEO100-01, -02, -03) and is awaiting decisions, supporting a multi-program, multi-country CNS oncology strategy based on its NEO platform.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- DOH Abu Dhabi grants IND clearance for NEO212, enabling UAE Phase 2
- Phase 1 dose escalation completed with 610 mg selected as Phase 2 dose
- Early clinical activity signals reported in recurrent GBM and brain metastases
- First international regulatory clearance establishes global path for NEO212
- Parallel UAE and U.S. FDA regulatory discussions for potential registrational path
- Additional NEO100 program applications may expand UAE clinical footprint
Negative
- UAE IND clearance is limited to research and is not marketing approval
- UAE patient enrollment requires IRB approval and protocol, brochure, label updates
- NEO212 and NEO100 remain unapproved investigational products with development risk
News Market Reaction – NTHI
On the day this news was published, NTHI gained 14.86%, reflecting a significant positive market reaction. Argus tracked a peak move of +20.0% during that session. Argus tracked a trough of -8.7% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $19M to the company's valuation, bringing the market cap to $147.05M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | NEO100 results update | Positive | -3.2% | Expanded 25-patient NEO100 dataset with remission and survival signals reported. |
| Nov 12 | NEO100 data update | Positive | +3.6% | Updated Phase 1/2a NEO100 data with response, PFS-6, and survival metrics. |
| Sep 10 | NEO212 FDA Phase II ok | Positive | +17.1% | FDA authorization to proceed with NEO212 Phase IIa/IIb after Phase I completion. |
| Jul 08 | GCC/MENA expansion deal | Positive | +3.6% | $50M non-binding term sheet to fund GCC & MENA clinical expansion platform. |
| Apr 14 | NEO100-01 enrollment | Positive | -12.1% | Update on nearing full enrollment of NEO100-01 Phase 2a malignant glioma trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial updates have produced mixed reactions, with several positive data releases followed by both strong gains and notable selloffs.
Over the past year, NeOnc has repeatedly highlighted clinical progress in CNS oncology. On Apr 14, 2025, the company discussed nearing full enrollment in the NEO100-01 Phase 2a trial. Subsequent updates on NEO100 and NEO212, including FDA authorization for a Phase II trial on Sep 10, 2025, and expanded NEO100 datasets on Nov 12 and Dec 15, 2025, underscored encouraging efficacy and safety. Today’s UAE IND clearance for NEO212 adds an international pathway, extending that clinical narrative beyond the U.S.
Historical Comparison
In the past year, NTHI issued 5 clinical trial updates with an average move of 1.8%. Today’s -5.05% reaction to new NEO212 IND clearance is weaker than prior same-tag responses.
Clinical news shows a progression from Phase 2 NEO100 enrollment and data readouts to FDA Phase II authorization for NEO212, now extended by UAE IND approval to support global Phase 2 development.
Regulatory & Risk Context
An effective S-3 shelf dated Jun 15, 2026 registers 555,554 existing and warrant-linked shares for resale by a stockholder. NeOnc receives proceeds only if the associated $9.00 Warrant is exercised for cash.
Key Terms
investigational new drug (ind) regulatory
institutional review board (irb) regulatory
blood-brain barrier medical
glioblastoma medical
brain metastases medical
fast-track regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates
Follows completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose
Adds an international clinical pathway alongside continuing U.S. FDA discussions on a potential registrational pathway for NEO212
CALABASAS, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, the Company’s orally administered perillyl alcohol-temozolomide carbamate conjugate being developed for patients with aggressive brain tumors. The authorization marks the first international regulatory clearance for NEO212 following completion of Phase 1 clinical evaluation and represents a significant step toward expanding the program into multiple global markets.
NEO212 recently completed the Phase 1 dose-escalation portion of its Phase 1/2 study, which established 610 mg as the recommended Phase 2 dose. In that study, the Company reported encouraging early signs of clinical activity, including potential durable disease stabilization, in heavily pretreated patients with recurrent glioblastoma (GBM) and brain metastases. NeOnc expects this authorization to support the advancement of NEO212 into Phase 2 clinical development while continuing discussions with the U.S. Food and Drug Administration regarding the design of a potential registrational pathway. The Company believes parallel regulatory and clinical activities across multiple jurisdictions may accelerate the overall development strategy for NEO212.
Under the terms of the DOH authorization, NeOnc must satisfy a number of conditions before patient enrollment in the UAE, including separate approval from the DOH Institutional Review Board (IRB) and amendments to the study protocol, investigator’s brochure, and product labeling. The DOH clearance applies to the conduct of clinical research and does not constitute marketing authorization.
The Company has also submitted applications to the Department of Health – Abu Dhabi for its NEO100 clinical programs, including NEO100-01, NEO100-02, and NEO100-03, and is currently awaiting regulatory decisions. If approved, these programs would further expand NeOnc’s clinical development footprint in the UAE and support the Company’s strategy of advancing multiple brain cancer and neurological therapeutic programs in parallel across key international markets.
“This clearance represents an important international milestone for NeOnc and for the NEO212 program,” said Amir Heshmatpour, Chief Executive Officer, Executive Chairman and President of NeOnc. “Brain cancers such as glioblastoma remain among the most difficult diseases in oncology, and patients urgently need new treatment options. We are grateful to the Department of Health – Abu Dhabi for its rigorous and collaborative review, and we look forward to working with investigators and healthcare institutions in the UAE as we advance NEO212 toward Phase 2 development.”
Glioblastoma remains one of the deadliest forms of cancer, with limited treatment options and poor long-term survival outcomes. NEO212 is designed to combine the chemotherapeutic temozolomide with perillyl alcohol in a single orally administered conjugate intended to improve delivery across the blood-brain barrier. The Company expects to work with healthcare institutions, investigators, and regulatory authorities in the UAE as clinical development activities advance.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The Company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The Company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit https://neonc.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Please refer to the “Risk Factors” section of our quarterly and annual reports on Form 10-Q and Form 10-K as filed with the Securities and Exchange Commission, along with other cautionary language in those reports and risk factors and other cautionary language in our subsequent filings with the Securities and Exchange Commission, which outline important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the fact that results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials, announced or published data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, and our product candidates are in preclinical and clinical stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
NEO100™ and NEO212™ are trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026
This press release was published by a CLEAR® Verified individual.
